Prognostic value of Mandard score and nodal status for recurrence patterns and survival after multimodal treatment of oesophageal adenocarcinoma.

"Disclosure M.I.v.B.H. is a consultant for Alesi Surgical, B. Braun, Johnson & Johnson, Medtronic, and Viatris, and received research grants from Stryker (all fees paid to the institution). H.W.M.v.L. has acted as a consultant for BMS, Daiichy, Eli Lilly and Company, MSD, Nordic Pharma Group/Taiho, and Servier, and has received unrestricted research grants from Amgen, Bayer Schering Pharma, BMS, Celgene, Eli Lilly and Company, GlaxoSmithKline Pharmaceuticals, Merck, MSD, Nordic Pharma Group, Philips, and Roche Pharmaceuticals. M.F.B. has received research funding from Celgene, Frame Therapeutics, and Lead Pharma, and acted as a consultant to Servier and Olympus. None of these companies were involved in the design, conduct, or analysis of this study or drafting of the manuscript and decision to publish. The authors declare no other conflict of interest."

"Funding The authors have no funding to declare."